Retinoic Acid Receptors (RARs) Agonist Pipeline Insight, 2022 report by DelveInsight offers comprehensive insights of the pipeline (under development) therapeutics scenario and growth prospects across Retinoic Acid Receptors (RARs) Agonist development.

Retinoic Acid Receptors (RARs) Agonist Pipeline Insight

&nbsp;
DelveInsight&rsquo;s, &ldquo;Retinoic Acid Receptor (RARs) Agonist - Pipeline Insight, 2025,&rdquo; report provides comprehensive insights about 15+ companies and 15+ pipeline drugs in Retinoic Acid Receptor (RARs) Agonist pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
<h2>Geography Covered</h2>
<ul>
<li>Global coverage</li>
</ul>
<h2>Retinoic Acid Receptor (RARs) Agonist Understanding</h2>
Retinoic Acid Receptor (RARs) Agonist: Overview
Retinoic acid receptors (RARs) are nuclear hormone receptors of the NR1B class, which function as heterodimers with retinoid X receptors (RXRs). The retinoic acid receptors (RAR&alpha;, RAR&beta;, and RAR&gamma;) are members of the nuclear receptor superfamily. Compounds which bind to and activate the RARs are termed retinoids and comprise both natural retinol (Vitamin A) metabolites and synthetic analogs. Upon binding of an agonist ligands to RAR results in dissociation of corepressor and recruitment of coactivator protein that, promotes transcription of the downstream target gene into mRNA and eventually protein. Several Retinoic Acid Receptors (RAR) agonists have therapeutic activity against a variety of cancer types. RAR agonists presenting novel structural and chemical features could therefore open new avenues for the discovery of leads against breast, lung and prostate cancer or leukemia.
<h2>Report Highlights</h2>
The companies and academics are working to assess challenges and seek opportunities that could influence Retinoic Acid Receptor (RARs) Agonist R&amp;D. The therapies under development are focused on novel approaches for Retinoic Acid Receptor (RARs) Agonist.
<h2>Retinoic Acid Receptor (RARs) Agonist Emerging Drugs Chapters</h2>
This segment of the Retinoic Acid Receptor (RARs) Agonist report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
&nbsp;
Retinoic Acid Receptor (RARs) Agonist Emerging Drugs
&nbsp;
Palovarotene: Clementia Pharmaceuticals (Ipsen)
Palovarotene is a RAR&gamma; agonist being developed as a potential treatment for patients with ultra-rare and debilitating bone diseases, including fibrodysplasia ossificans progressiva (FOP) and multiple osteochondromas (MO), as well as other conditions including dry eye disease. Palovarotene had received rare pediatric disease and breakthrough therapy designations for the treatment of an ultra-rare bone disorder.
&nbsp;
IRX 5183: Allergan (AbbVie)
IRX 5183 is a selective, orally available, third generation vitamin A derivative and first in class Retinoic Acid Receptor alpha (RAR&alpha;) agonist. IRX 5183 is a drug that is designed to cause cancer cells to mature and then die. The drug is in Phase I/II clinical development for the treatment of cancer.
Further product details are provided in the report&hellip;&hellip;..
<h2>Retinoic Acid Receptor (RARs) Agonist: Therapeutic Assessment</h2>
This segment of the report provides insights about the different Retinoic Acid Receptor (RARs) Agonist drugs segregated based on following parameters that define the scope of the report, such as:
<ul>
<li>Major&nbsp;Players working on Retinoic Acid Receptor (RARs) Agonist</li>
</ul>
There are approx. 15+ key companies which are developing the Retinoic Acid Receptor (RARs) Agonist. The companies which have their Retinoic Acid Receptor (RARs) Agonist drug candidates in the most advanced stage, i.e. Phase III include, Clementia Pharmaceuticals (Ipsen).
<h2>Phases</h2>
DelveInsight&rsquo;s report covers around 15+ products under different phases of clinical development like
<ul>
<li>Late-stage products (Phase III and</li>
<li>Mid-stage products (Phase II and</li>
<li>Early-stage products (Phase I/II and Phase I) along with the details of</li>
<li>Pre-clinical and Discovery stage candidates</li>
<li>Discontinued &amp; Inactive candidates</li>
<li>Route of Administration</li>
</ul>
&nbsp;
Retinoic Acid Receptor (RARs) Agonist pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as 
<ul>
<li>Infusion</li>
<li>Intradermal</li>
<li>Intramuscular</li>
<li>Intranasal</li>
<li>Intravaginal</li>
<li>Oral</li>
<li>Parenteral</li>
<li>Subcutaneous</li>
<li>Topical</li>
<li>Molecule Type</li>
</ul>
&nbsp;
Products have been categorized under various Molecule types such as
<ul>
<li>Vaccines</li>
<li>Monoclonal Antibody</li>
<li>Peptides</li>
<li>Polymer</li>
<li>Small molecule</li>
<li>Product Type</li>
</ul>
Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.
<h2>Retinoic Acid Receptor (RARs) Agonist: Pipeline Development Activities</h2>
The report provides insights into different therapeutic candidates in phase III, II, I, preclinical and discovery stage. It also analyses Retinoic Acid Receptor (RARs) Agonist therapeutic drugs key players involved in developing key drugs.
&nbsp;
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Retinoic Acid Receptor (RARs) Agonist drugs.
<h2>Retinoic Acid Receptor (RARs) Agonist Report Insights</h2>
<ul>
<li>Retinoic Acid Receptor (RARs) Agonist Pipeline Analysis</li>
<li>Therapeutic Assessment</li>
<li>Unmet Needs</li>
<li>Impact of Drugs</li>
</ul>
<h2>Retinoic Acid Receptor (RARs) Agonist Report Assessment</h2>
<ul>
<li>Pipeline Product Profiles</li>
<li>Therapeutic Assessment</li>
<li>Pipeline Assessment</li>
<li>Inactive drugs assessment</li>
<li>Unmet Needs</li>
</ul>
<h2>Key Questions</h2>
Current Scenario and Emerging Therapies:
<ul>
<li>How many companies are developing Retinoic Acid Receptor (RARs) Agonist drugs?</li>
<li>How many Retinoic Acid Receptor (RARs) Agonist drugs are developed by each company?</li>
<li>How many emerging drugs are in mid-stage, and late-stage of development for Retinoic Acid Receptor (RARs) Agonist?</li>
<li>What are the key collaborations (Industry&ndash;Industry, Industry&ndash;Academia), Mergers and acquisitions, licensing activities related to the Retinoic Acid Receptor (RARs) Agonist therapeutics?</li>
<li>What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?</li>
<li>What are the clinical studies going on for Retinoic Acid Receptor (RARs) Agonist and their status?</li>
<li>What are the key designations that have been granted to the emerging drugs?</li>
</ul>
&nbsp;
&nbsp;

Introduction
Executive Summary
Retinoic Acid Receptor (RARs) Agonist: Overview
<ul>
<li>Structure</li>
<li>Mechanism of Action</li>
</ul>
Pipeline Therapeutics
<ul>
<li>Comparative Analysis</li>
</ul>
Therapeutic Assessment
<ul>
<li>Assessment by Product Type</li>
<li>Assessment by Stage and Product Type</li>
<li>Assessment by Route of Administration</li>
<li>Assessment by Stage and Route of Administration</li>
<li>Assessment by Molecule Type</li>
<li>Assessment by Stage and Molecule Type</li>
</ul>
Retinoic Acid Receptor (RARs) Agonist &ndash; DelveInsight&rsquo;s Analytical Perspective
In-depth Commercial Assessment
<ul>
<li>Retinoic Acid Receptor (RARs) Agonist companies&rsquo; collaborations, Licensing, Acquisition -Deal Value Trends</li>
</ul>
Retinoic Acid Receptor (RARs) Agonist Collaboration Deals
<ul>
<li>Company-Company Collaborations (Licensing / Partnering) Analysis</li>
<li>Company-University Collaborations (Licensing / Partnering) Analysis</li>
</ul>
Late Stage Products (Phase III) 
<ul>
<li>Comparative Analysis</li>
</ul>
Palovarotene: Clementia Pharmaceuticals (Ipsen)
<ul>
<li>Product Description</li>
<li>Research and Development</li>
<li>Product Development Activities</li>
</ul>
Drug profiles in the detailed report&hellip;..
Mid Stage Products (Phase II)
<ul>
<li>Comparative Analysis</li>
</ul>
Tretinoin topical: Avecho Biotechnology
<ul>
<li>Product Description</li>
<li>Research and Development</li>
<li>Product Development Activities</li>
</ul>
Drug profiles in the detailed report&hellip;..
Early Stage Products (Phase I/II) 
<ul>
<li>Comparative Analysis</li>
</ul>
IRX 5183: Allergan (AbbVie)
<ul>
<li>Product Description</li>
<li>Research and Development</li>
<li>Product Development Activities</li>
</ul>
Drug profiles in the detailed report&hellip;..
Pre-clinical and Discovery Stage Products
<ul>
<li>Comparative Analysis</li>
</ul>
Fenretinide intravenous: SciTech Development
<ul>
<li>Product Description</li>
<li>Research and Development</li>
<li>Product Development Activities</li>
</ul>
Drug profiles in the detailed report&hellip;..
Inactive Products
<ul>
<li>Comparative Analysis</li>
</ul>
Retinoic Acid Receptor (RARs) Agonist Key Companies
Retinoic Acid Receptor (RARs) Agonist Key Products
Retinoic Acid Receptor (RARs) Agonist- Unmet Needs
Retinoic Acid Receptor (RARs) Agonist- Market Drivers and Barriers
Retinoic Acid Receptor (RARs) Agonist- Future Perspectives and Conclusion
Retinoic Acid Receptor (RARs) Agonist Analyst Views
Retinoic Acid Receptor (RARs) Agonist Key Companies
Appendix
&nbsp;

Retinoic Acid Receptors (RARs) Agonist - Pipeline Insight, 2025

Retinoic Acid Receptors (RARs) Agonist Pipeline Insights, 2025 report by DelveInsight offers comprehensive insights of the pipeline (under development) therapeutics scenario and growth pro...